GoKawiilIn the version of the article initially published, the Competing interests section was incorrect and has now been amended to “N.S., B.B.L. and M.R.B. are co-founders and members of the Scientific Advisory Board of Biosyft, LLC, and A.E.E. is the Chief Executive Officer of Biosyft, LLC. Biosyft is developing and commercializing applications related to some of the technologies described in this manuscript. While the specific findings reported here are not directly aligned with Biosyft’s current commercial activities, given the related nature of the technology and its potential applications, the authors disclose these relationships. The other authors declare no competing interests” in the HTML and PDF versions of the article.
Author Correction: Endocannabinoids facilitate reward engagement through retrograde gain control
Why This Matters
This correction highlights the importance of transparency in scientific research, especially when industry affiliations may influence study outcomes. For the tech industry and consumers, understanding these disclosures ensures trust in the development of new neurotechnologies and their potential applications. Clear conflict of interest statements help maintain integrity and credibility in scientific advancements related to endocannabinoid research.
Key Takeaways
- Transparency in research disclosures is crucial for trust.
- Industry affiliations can influence scientific findings and their applications.
- Accurate conflict of interest statements protect scientific integrity.
Explore topics:
endocannabinoids
biosyft
scientific advisory board
retrograde gain control
reward engagement
Get alerts for these topics